Next Article in Journal
Immunohistochemical Assessment of Expression of Centromere Protein—A (CENPA) in Human Invasive Breast Cancer
Next Article in Special Issue
Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy
Previous Article in Journal
Transcription Inhibition as a Therapeutic Target for Cancer
Previous Article in Special Issue
Carbohydrate Mimetic Peptides Augment Carbohydrate-Reactive Immune Responses in the Absence of Immune Pathology
Cancers 2011, 3(4), 4191-4211; doi:10.3390/cancers3044191
Review

Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines

1,†
,
1,2,†
,
2,3
,
2,4
,
1
,
1
,
1,2
,
2,4
,
2,5
 and
1,2,*
1 Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA 2 The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University, School of Medicine, St. Louis, MO 63110, USA 3 The Genome Institute at Washington University School of Medicine, St. Louis, MO 63108, USA 4 Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA 5 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 17 September 2011 / Revised: 31 October 2011 / Accepted: 9 November 2011 / Published: 25 November 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [1337 KB, uploaded 25 November 2011]   |   Browse Figures

Abstract

New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time decision-making with the potential to affect diagnosis, prognosis, and treatment, and has opened the door towards personalized medicine. A promising strategy is the identification of mutated tumor antigens, and the design of personalized cancer vaccines. Supporting this notion are preliminary analyses of the epitope landscape in breast cancer suggesting that individual tumors express significant numbers of novel antigens to the immune system that can be specifically targeted through cancer vaccines.
Keywords: cancer genome sequencing; unique tumor antigen; DNA vaccine cancer genome sequencing; unique tumor antigen; DNA vaccine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Li, L.; Goedegebuure, P.; Mardis, E.R.; Ellis, M.J.; Zhang, X.; Herndon, J.M.; Fleming, T.P.; Carreno, B.M.; Hansen, T.H.; Gillanders, W.E. Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines. Cancers 2011, 3, 4191-4211.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert